Could be a combination of options expiry day and institutional rebalancing at the end of a Qtr.I note there was a 15Mill cross trade and a number of other cross trades.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%